Replies to post #169359 on Biotech Values

[genisi]

GILD's SVR12 results from the LONESTAR trial 8 weeks or 12 weeks

Interpretation
These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis. Further clinical trials are needed to establish the best treatment duration and to further assess the contribution of ribavirin.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62121-2/abstract